Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Clinical Pharmacology and Therapeutics
|
November 4, 2011
A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis
J W Mandema, D H Salinger, S W Baumgartner, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 26, 2013
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis
M G Dodds, D H Salinger, J Mandema, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
March 28, 2013
Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study
D H Salinger, S Mundle, A Regi, et al.
Clinical Pharmacology and Therapeutics
|
March 20, 2009
Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy
J S McCune, A Batchelder, K A Guthrie, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Clinical Pharmacology and Therapeutics
|
November 4, 2011
A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis
J W Mandema, D H Salinger, S W Baumgartner, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 26, 2013
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis
M G Dodds, D H Salinger, J Mandema, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
March 28, 2013
Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study
D H Salinger, S Mundle, A Regi, et al.
Clinical Pharmacology and Therapeutics
|
March 20, 2009
Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy
J S McCune, A Batchelder, K A Guthrie, et al.
Page
of 1